These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3532615)

  • 1. [Is it necessary to confirm the results of drug screening with a 2d analytical method?].
    Vu Duc T; Vernay A
    Soz Praventivmed; 1986; 31(4-5):199-201. PubMed ID: 3532615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine testing in the detection of drugs of abuse.
    Schwartz RH
    Arch Intern Med; 1988 Nov; 148(11):2407-12. PubMed ID: 3056313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine Drug Screens: Common False Positives and Negatives.
    Daniel J
    S D Med; 2015 Jun; 68(6):262-3. PubMed ID: 26137727
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of a direct high-capacity target screening approach for urine drug testing using liquid chromatography-time-of-flight mass spectrometry.
    Saleh A; Stephanson NN; Granelli I; Villén T; Beck O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Nov; 909():6-13. PubMed ID: 23153637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEDIA for screening drugs of abuse in urine and the effect of adulterants.
    Wu AH; Forte E; Casella G; Sun K; Hemphill G; Foery R; Schanzenbach H
    J Forensic Sci; 1995 Jul; 40(4):614-8. PubMed ID: 7595298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problems of mass urine screening for misused drugs.
    Morgan JP
    J Psychoactive Drugs; 1984; 16(4):305-17. PubMed ID: 6394729
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in whole blood of drivers involved in road accidents.
    Pelletti G; Garagnani M; Rossi F; Roffi R; Barone R; Pelotti S
    Forensic Sci Int; 2019 Jan; 294():27-33. PubMed ID: 30447484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of drugs-of-abuse testing in urine under blind conditions: an AACC study.
    Frings CS; Battaglia DJ; White RM
    Clin Chem; 1989 May; 35(5):891-4. PubMed ID: 2720992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for drugs in forensic blood samples using EMIT urine assays.
    Gjerde H; Christophersen AS; Skuterud B; Klemetsen K; Mørland J
    Forensic Sci Int; 1990 Feb; 44(2-3):179-85. PubMed ID: 2180797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical issues associated with urine testing of substances of abuse.
    Eskridge KD; Guthrie SK
    Pharmacotherapy; 1997; 17(3):497-510. PubMed ID: 9165553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of an ELISA method for screening methadone in postmortem blood.
    Juhascik M; Habbel S; Barron W; Behonick G
    J Anal Toxicol; 2006 Oct; 30(8):617-20. PubMed ID: 17132262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [False positive screening for drugs of abuse].
    Watine J
    Ann Biol Clin (Paris); 2003; 61(3):367-8. PubMed ID: 12825552
    [No Abstract]   [Full Text] [Related]  

  • 13. Method comparison of the Ortho Vitros Fusion 5,1 chemistry analyzer and the Roche COBAS Integra 400 for urine drug screen testing in the emergency department.
    Johnson-Davis KL; Thompson CD; Clark CJ; McMillin GA; Lehman CM
    J Anal Toxicol; 2012 Jun; 36(5):345-8. PubMed ID: 22582270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples.
    Holler JM; Bosy TZ; Klette KL; Wiegand R; Jemionek J; Jacobs A
    J Anal Toxicol; 2004 Sep; 28(6):489-93. PubMed ID: 15516301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Substance abuse analysis of biological materials].
    Christophersen AS; Mørland J
    Tidsskr Nor Laegeforen; 1991 Nov; 111(27):3300-3. PubMed ID: 1957291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fast screening procedure for ketamine and metabolites in urine samples with tandem mass spectrometry.
    Lin HR; Lin HL; Lee SF; Liu C; Lua AC
    J Anal Toxicol; 2010 Apr; 34(3):149-54. PubMed ID: 20406539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Cozart microplate ELISA for detection of opiates in hair.
    Cooper G; Wilson L; Reid C; Baldwin D; Hand C; Spiehler V
    J Anal Toxicol; 2003; 27(8):581-6. PubMed ID: 14670137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine drug screening: chemical McCarthyism.
    Lundberg GD
    N Engl J Med; 1972 Oct; 287(14):723-4. PubMed ID: 5055428
    [No Abstract]   [Full Text] [Related]  

  • 20. False positives and negatives in routine testing for drugs of abuse.
    Notarianni LJ; Belk D; Collins AJ
    Lancet; 1995 Apr; 345(8957):1115. PubMed ID: 7715360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.